Key regions: France, India, United Kingdom, South Korea, Japan
The Multiple Sclerosis Drugs market in Kazakhstan has been steadily growing in recent years.
Customer preferences: Kazakhstan's healthcare system is primarily funded by the government, and patients typically rely on state-run medical institutions for treatment. However, there is a growing demand for private healthcare services, particularly among the middle and upper classes. Patients with Multiple Sclerosis (MS) often require long-term treatment and care, which can be expensive. As a result, many patients may prefer to seek out private healthcare options, which offer a wider range of treatment options and more personalized care.
Trends in the market: The market for MS drugs in Kazakhstan is driven by a number of factors, including increasing awareness of the disease and its treatment options, as well as the growing availability of new and innovative drugs. In recent years, a number of new drugs have been introduced to the market, offering patients more effective and targeted treatment options. Additionally, there has been a growing focus on early diagnosis and treatment of MS, which has helped to increase demand for MS drugs in the country.
Local special circumstances: Kazakhstan has a relatively high prevalence of MS, particularly in the northern regions of the country. This has led to a growing demand for MS drugs, as well as increased investment in research and development. Additionally, there is a growing focus on improving the overall quality of healthcare in the country, which has helped to drive demand for MS drugs and other treatments.
Underlying macroeconomic factors: Kazakhstan's economy has been growing steadily in recent years, driven by a number of factors including rising oil prices and increased investment in infrastructure and other sectors. This has helped to drive demand for healthcare services, including MS drugs. Additionally, the government has been investing heavily in healthcare infrastructure and services, which has helped to improve access to care and increase demand for MS drugs and other treatments. Overall, the outlook for the MS drugs market in Kazakhstan is positive, with strong demand expected to continue in the coming years.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
